SCHEMBL1085646

SCHEMBL1085646

Cc1cccc2c1NC(=O)c1ccc(C(F)(F)F)nc1N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 12/20 0.42
DAO P14920 1/20 0.40
NR1I2 O75469 4/20 0.35
CYP1A2 P05177 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CES1 P23141 1/20 0.35
CREBBP Q92793 1/20 0.35
PLK4 O00444 1/20 0.34
AURKA O14965 1/20 0.34
CHEK2 O96017 1/20 0.34
LCK P06239 1/20 0.34
CDK2 P24941 1/20 0.34
MAPK8 P45983 1/20 0.34
CSNK1D P48730 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
BLK P51451 1/20 0.34
CDK5 Q00535 1/20 0.34
STK3 Q13188 1/20 0.34
AURKB Q96GD4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085599 0.85 BRS3 (0.41) BRS3NR1I2CYP1A2SMN1; SMN2CES1
SCHEMBL1085752 0.74 BRS3 (0.49) BRS3NR1I2
SCHEMBL8790953 0.74 CYP1A2 (0.65) DAOCYP1A2SMN1; SMN2CREBBPPLK4
SCHEMBL14815543 0.71 CYP1A2 (0.51) BRS3CYP1A2SMN1; SMN2PLK4AURKA
SCHEMBL11528200 0.65 CYP1A2 (0.56) CYP1A2SMN1; SMN2PLK4AURKACHEK2
SCHEMBL12016687 0.64 CREBBP (0.48) DAOCYP1A2CREBBPPOLB
SCHEMBL17803345 0.64 CHEK1 (0.42) DAOCYP1A2SMN1; SMN2CES1PLK4
SCHEMBL1085891 0.62 BRS3 (0.41) BRS3NR1I2
SCHEMBL26150217 0.62 PDE4B (0.43)
SCHEMBL1085611 0.61 BRS3 (0.48) BRS3NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153626-B2 Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-04-10 US disclosed
US-20100317645-A1 SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS MERCK SHARP & DOHME LLC 2010-12-16 US disclosed
EP-2102201-B1 SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS MERCK SHARP & DOHME (US) 2010-10-13 EP disclosed
EP-2102201-A2 SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS Merck & Co., Inc. (US) 2009-09-23 EP disclosed
WO-2008073311-A2 SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS MERCK & CO., INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317645-A1 SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS BRS3, BRSK1, BRSK2 BRS3 1/4885DAO 3575/4885NR1I2 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.